Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Articles published by Galderma

< Previous 1 2 3 Next >

PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis

Today 1:00 EDT

From Galderma

Via Business Wire

Galderma Signs Agreement to Acquire ZO Skin Health, Strengthening Its Physician-Dispensed Skincare Offering

October 14, 2026

From Galderma

Via Business Wire

New Galderma Research Reveals More Than Half of Women Mistake Menopause-Related Skin Changes for Signs of Ageing

October 13, 2026

From Galderma

Via Business Wire

Fall Clinical 2026: Galderma Presents New Three-Year Nemluvio® Data Showing Deep and Lasting Skin Lesion and Itch Responses in Patients With Atopic Dermatitis Aged 12 and Older

October 08, 2026

From Galderma

Via Business Wire

30 Years of Restylane®: Reshaping the Aesthetics Field Through Science-Led, Patient-Centric Innovation

October 06, 2026

From Galderma

Via Business Wire

EADV 2026: Galderma’s New Data Show Sustained Improvements with Nemluvio® (nemolizumab) for up to Three Years in Patients With Moderate-to-severe Atopic Dermatitis

September 30, 2026

From Galderma

Via Business Wire

EADV 2026: Galderma to Unveil New Data Advancing Understanding of Skin Diseases, Skin Longevity, and Real-world Patient Experiences

September 23, 2026

From Galderma

Via Business Wire

Galderma Begins Trading in the Swiss Market Index, Joining Switzerland's Leading Blue Chip Companies

September 21, 2026

From Galderma

Via Business Wire

Galderma’s Restylane® Volyme™ Demonstrates High Effectiveness, Satisfaction and a Robust Safety Profile in Chinese Patients With Temple Hollowing

September 16, 2026

From Galderma

Via Business Wire

Galderma Receives European Union Approval for Restylane® Shaype™: the First-and-Only Bone-Mimicking Hyaluronic Acid Injectable for Facial Shaping

August 11, 2026

From Galderma

Via Business Wire

Galderma Launches Alastin® in Japan and Key Markets Across Asia Pacific, Expanding Its Footprint in the Region

July 20, 2026

From Galderma

Via Business Wire

Landmark Global Galderma Survey Shows 9 out of 10 People Are Affected by Skin Quality Concerns

July 07, 2026

From Galderma

Via Business Wire

Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States

July 01, 2026

From Galderma

Via Business Wire

Galderma Unveils New Global Survey Data Exploring the Evolving Expectations and Experiences of Patients and Healthcare Professionals With Anti-wrinkle Treatments

June 11, 2026

From Galderma

Via Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch

May 22, 2026

From Galderma

Via Business Wire

Galderma Launches New Alastin Regenerating Skin Nectar with TriHex+™, Powered by Its Next-Generation TriHex Technology® Regenerative Platform

April 16, 2026

From Galderma

Via Business Wire

Interim Data From Two Ongoing Investigator-initiated Trials Highlight the Role of Sculptra® and Restylane® in Addressing Aesthetic Changes Associated With Weight Loss Medications and Menopause

April 09, 2026

From Galderma

Via Business Wire

Galderma Debuts ALASTIN Signature Practices in Partnership With Leading Aesthetic Practices to Elevate Regenerative, Peri-Procedural Skincare

April 07, 2026

From Galderma

Via Business Wire

AAD 2026: Galderma Showcases Latest Evidence Supporting Its Full-Spectrum, Science-Driven Solutions for Diverse Skin Needs

March 24, 2026

From Galderma

Via Business Wire

Galderma Receives U.S. FDA Approval for Restylane® Contour™ for the Correction of Temple Hollowing

March 23, 2026

From Galderma

Via Business Wire

Galderma Publishes Invitation and Agenda for Its 2026 Annual General Meeting

March 20, 2026

From Galderma

Via Business Wire

AMWC 2026: Galderma Showcases Category‑leading Innovation With a Comprehensive Portfolio and Holistic, Future‑focused Aesthetic Strategies

March 17, 2026

From Galderma

Via Business Wire

Galderma Buys Back Shares Worth CHF 232 Million in the Context of Accelerated Bookbuild Offering

March 11, 2026

From Galderma

Via Business Wire

Galderma Introduces Cetaphil AM/PM Antioxidant Serums, a New Science-Driven Defense and Recovery System for Sensitive Skin

March 09, 2026

From Galderma

Via Business Wire

Galderma’s Nemluvio® (nemolizumab) Demonstrates Long-Term Disease Control in Prurigo Nodularis up to Three Years

February 27, 2026

From Galderma

Via Business Wire

Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics

February 25, 2026

From Galderma

Via Business Wire

Galderma Announces Appointment of New Chief Financial Officer

February 16, 2026

From Galderma

Via Business Wire

We Are All Sculptra: First-of-its-Kind Galderma Initiative to Demonstrate How Everyone Can Benefit from Sculptra’s Regenerative Properties

February 12, 2026

From Galderma

Via Business Wire

Galderma Expands Restylane® Portfolio in Japan With Launch of OBT™ Hyaluronic Acid Injectables Restylane Defyne™ and Refyne™

February 11, 2026

From Galderma

Via Business Wire

Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission

February 02, 2026

From Galderma

Via Business Wire

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.